Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Sep 10;23(14):1893-901.
doi: 10.1097/QAD.0b013e32832dc041.

Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents

Kunjal Patel  1 , Xue Ming, Paige L Williams, Kevin R Robertson, James M Oleske, George R Seage 3rd; International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team
Collaborators, Affiliations
Clinical Trial

Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents

Kunjal Patel et al. AIDS. .

Abstract

Objectives: Prior to antiretroviral treatment, HIV-infected children frequently developed encephalopathy, resulting in debilitating morbidity and mortality. This is the first large study to evaluate the impact of HAART and central nervous system (CNS)-penetrating antiretroviral regimens on the incidence of HIV encephalopathy and survival after diagnosis of HIV encephalopathy among perinatally infected children.

Design: A total of 2398 perinatally HIV-infected children with at least one neurological examination were followed in a US-based prospective cohort study conducted from 1993 to 2007.

Methods: Trends in incidence rates over calendar time were described and Cox regression models were used to estimate the effects of time-varying HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy and on survival after diagnosis of HIV encephalopathy.

Results: During a median of 6.4 years of follow-up, 77 incident cases of HIV encephalopathy occurred [incidence rate 5.1 cases per 1000 person-years, 95% confidence interval (CI) 4.0-6.3]. A 10-fold decline in incidence was observed beginning in 1996, followed by a stable incidence rate after 2002. HAART regimens were associated with a 50% decrease (95% CI 14-71%) in the incidence of HIV encephalopathy compared with non-HAART regimens. High CNS-penetrating regimens were associated with a substantial survival benefit (74% reduction in the risk of death, 95% CI 39-89%) after HIV encephalopathy diagnosis compared with low CNS-penetrating regimens.

Conclusion: A dramatic decrease in the incidence of HIV encephalopathy occurred after the introduction of HAART. The use of HAART was highly effective in reducing the incidence of HIV encephalopathy among perinatally infected children and adolescents. Effective CNS-penetrating antiretroviral regimens are important in affecting survival after diagnosis of HIV encephalopathy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Incidence of HIV encephalopathy and percentage of children on HAART from 1994 to 2006.
See this image and copyright information in PMC

Comment in

References

    1. Epstein LG, Sharer LR, Joshi VV, Fojas MM, Koenigsberger MR, Oleske JM. Progressive encephalopathy in children with acquired immune deficiency syndrome. Ann Neurol. 1985;17:488–496. - PubMed
    1. Belman AL, Ultmann MH, Horoupian D, Novick B, Spiro AJ, Rubinstein A, et al. Neurological complications in infants and children with acquired immune deficiency syndrome. Ann Neurol. 1985;18:560–566. - PubMed
    1. Epstein LG, Sharer LR, Oleske JM, Connor EM, Goudsmit J, Bagdon L, et al. Neurologic manifestations of human immunodeficiency virus infection in children. Pediatrics. 1986;78:678–687. - PubMed
    1. Epstein LG, Sharer LR, Goudsmit J. Neurological and neuropathological features of human immunodeficiency virus infection in children. Ann Neurol. 1988;23(Suppl):S19–S23. - PubMed
    1. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep. 1987;36(1S Suppl):3S–15S. - PubMed

Publication types

MeSH terms

Substances